Estrogen and progesterone receptors in breast cancer - current state of knowledge
Journal Title: Współczesna Onkologia - Year 2005, Vol 9, Issue 9
Abstract
The expression of estrogen and progesterone receptors provides strong and useful predictive factors. As the response to hormonal treatment is closely related to the content of estrogen and progesterone receptors in breast cancer, an assessment of the expression of these receptors allows us to predict the response of the cancer cells to hormonal treatment. The expression of estrogen and progesterone receptors is a weak prognostic factor. Statistically significant, positive prognostic effects of estrogen and progesterone receptor expression can only be shown in studies with large numbers of cases. In small or medium scale studies, the prognostic influence of the expression of estrogen and progesterone receptors is weak or absent. For almost four decades, the action of estrogens was attributed to one receptor. However, in 1996, a new estrogen receptor, estrogen receptor beta, was discovered. The first, well known and well characterized receptor, described five decades ago, was defined as estrogen receptor alpha. Estrogen receptor beta is encoded by a different gene to estrogen receptor alpha. The progesterone receptor also has two isoforms: A and B. Both progesterone receptors are encoded by the same gene, but different promoters are used for its transcription. The structure of both proteins is very similar. Nowadays, three methods are used for the assessment of the expression of steroid receptor content in breast cancers: the Ligand Binding Assay (LBA), Enzyme Immuno Assay (EIA) and Immuno Histo/Cytochemical Assay (IHA/ICA). The results of assessments performed with the use of these methods are similar.
Authors and Affiliations
Janusz Piekarski
Keywords
Related Articles
- EP ID EP154551
- DOI -
- Views 79
- Downloads 0
Radiochemioterapia glejaka wielopostaciowego powikłana wielonarządową grzybicą kropidlakową – opis przypadku
Od niedawna standardem leczenia chorych na glejaka jest zabieg chirurgiczny z uzupełniającą radioterapią skojarzoną z podawaniem temozolomidu. W trakcie chemioradioterapii chorej na glejaka wystąpiła ostra niewydolność...
Brachyterapia HDR nowotworów skóry – doświadczenie Wielkopolskiego Centrum Onkologii
Cel pracy: Analizie poddano grupę chorych na nowotwór skóry leczonych metodą brachyterapii HDR. Materiał i metody: Od maja 1999 r. do maja 2004 r. leczono metodą brachyterapii HDR w Wielkopolskim Centrum Onkologii 179 c...
Toxicity of g-csf given during radiotherapy in lung cancer
Introduction: The use of white blood cell growth factors (WBCGF) (g-csf, gm-csf) is recommended in chemotherapy-induced febrile neutropenia or prophylactically for cases treated with some chemotherapy regimens. Due to la...
Clinical utility of complementary measurements standard tumor markers and cytokines in patients with cervical cancer
We aimed to relate the levels of serum tumour markers (CEA, CA 125, CYFRA 21.1) and cytokines (IL-6, VEGF) in cervical cancer patients to the clinicopathologic features of the disease and to estimate the value of these...
PSA bounce phenomenon after External Beam Radiation Therapy for prostate cancer.
Introduction to clinical practice of PSA antigen altered the therapeutic approach to treatment of prostate cancer. The PSA antigen was defined as sensitive marker for monitoring of prostate cancer. At treated with radio...